Beigene Stock

Beigene ROE

Delisted·Jun 18, 2026

The Return on Equity (ROE) of Beigene (6160.HK) as of Aug 24, 2026 is 6.77 %. In the previous year, Return on Equity (ROE) was -19.35 % — a change of -134.98% (higher).

ROE

6.77 %

YoY

-134.98%

Last updated:

In 2026, Beigene's return on equity (ROE) was 6.77 %, a -134.98% increase from the -19.35 % ROE in the previous year.

The Beigene ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-38.42 USD
Jan 1, 2019
-96.96 USD
Jan 1, 2020
-42.00 USD
Jan 1, 2021
-23.35 USD
Jan 1, 2022
-45.71 USD
Jan 1, 2023
-24.93 USD
Jan 1, 2024
-19.35 USD
Jan 1, 2025
6.77 USD
The Beigene ROE history
YEARROEYoY
6.77 %-134.98%
-19.35 %-22.37%
-24.93 %-45.47%
-45.71 %+95.77%
-23.35 %-44.40%
-42.00 %-56.69%
-96.96 %+152.37%
-38.42 %+182.36%
-13.61 %-59.72%
-33.78 %-160.20%
56.11 %-179.11%
-70.93 %
Access this data via the Eulerpool API

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

ROE Details

Decoding Beigene's Return on Equity (ROE)

Beigene's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Beigene's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Beigene's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Beigene’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Beigene stock

Return on Equity (ROE) of Beigene is 6.77 % in 2026.

Return on Equity (ROE) of Beigene changed from -19.35 % to 6.77 %, representing a -134.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Beigene since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Beigene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Beigene

All Key Metrics — Beigene